The funds will help advance the company's collection of gene therapy programs, support novel gene therapy design, invest in the company's technology platform, and expand Neurogene's adeno-associated virus (AAV) vector good manufacturing practice manufacturing capabilities. Neurogene's lead programs use AAV vector-based gene therapy technology to treat rare, neurological diseases.

The round of financing was led by EcoR1 Capital, with participation from existing and new investors.

Regulatory Roundup: Designations come through before year's end
This week's Regulatory Roundup covers activities from November 30 to December 4 and is filled with breakthrough, orphan, and rare disease designations...